BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 15950315)

  • 21. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
    Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
    J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
    Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
    Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs.
    Gradowski JF; Mantha GS; Hunt JL; Dacic S
    Diagn Mol Pathol; 2007 Jun; 16(2):87-90. PubMed ID: 17525677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
    Awaya H; Takeshima Y; Furonaka O; Kohno N; Inai K
    J Clin Pathol; 2005 Oct; 58(10):1076-80. PubMed ID: 16189154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
    Lee J; Jang KT; Ki CS; Lim T; Park YS; Lim HY; Choi DW; Kang WK; Park K; Park JO
    Cancer; 2007 Apr; 109(8):1561-9. PubMed ID: 17354229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene.
    Fong Y; Lin YS; Liou CP; Li CF; Tzeng CC
    Respirology; 2010 May; 15(4):700-5. PubMed ID: 20409020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.
    Westra WH; Baas IO; Hruban RH; Askin FB; Wilson K; Offerhaus GJ; Slebos RJ
    Cancer Res; 1996 May; 56(9):2224-8. PubMed ID: 8616876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer.
    Mammano E; Belluco C; Sciro M; Mencarelli R; Agostini M; Michelotto M; Marchet A; Nitti D
    Anticancer Res; 2006; 26(5A):3547-50. PubMed ID: 17094480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor gene mutations in early pulmonary adenocarcinomas.
    Nakamura H; Kawasaki N; Taguchi M; Kato H
    Ann Thorac Cardiovasc Surg; 2007 Apr; 13(2):87-92. PubMed ID: 17505415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
    Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
    Sakamoto H; Shimizu J; Horio Y; Ueda R; Takahashi T; Mitsudomi T; Yatabe Y
    J Pathol; 2007 Jul; 212(3):287-94. PubMed ID: 17534846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations.
    Marchetti A; Pellegrini S; Bertacca G; Buttitta F; Gaeta P; Carnicelli V; Nardini V; Griseri P; Chella A; Angeletti CA; Bevilacqua G
    J Pathol; 1998 Mar; 184(3):240-6. PubMed ID: 9614374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
    Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
    Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors.
    Franco-Hernandez C; Martinez-Glez V; Arjona D; de Campos JM; Isla A; Gutierrez M; Vaquero J; Rey JA
    Cancer Genet Cytogenet; 2007 Feb; 173(1):63-7. PubMed ID: 17284372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of CYP19A1 polymorphisms with risks for atypical adenomatous hyperplasia and bronchioloalveolar carcinoma in the lungs.
    Kohno T; Kakinuma R; Iwasaki M; Yamaji T; Kunitoh H; Suzuki K; Shimada Y; Shiraishi K; Kasuga Y; Hamada GS; Furuta K; Tsuta K; Sakamoto H; Kuchiba A; Yamamoto S; Kanai Y; Tsugane S; Yokota J
    Carcinogenesis; 2010 Oct; 31(10):1794-9. PubMed ID: 20688833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.
    Tomonaga N; Nakamura Y; Yamaguchi H; Ikeda T; Mizoguchi K; Motoshima K; Doi S; Nakatomi K; Iida T; Hayashi T; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2013 Sep; 14(5):521-6. PubMed ID: 23786997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.